Jian Sun

Dr. Jian Sun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
BSBin Shang
Bin Shang
XLXiangguo Li
Xiangguo Li
YXYu Xu
Yu Xu
WRWenxin Ren
Wenxin Ren
JWJunren Wang
Junren Wang
JSJian Sun
Jian Sun
Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. We aim to obtain a better understanding of the clinical status and disease burden of patients with asthma in China. A retrospective study was carried out based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (available data from 38 hospitals). The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to Global Initiative for Asthma 2020 (GINA 2020). The results revealed that the majority (75.0%) of patients suffered from mild asthma. Patients treated with inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) at emergency department visits had lower frequencies of exacerbations compared with non-ICS/LABA-treated patients. The incidence rates for 1, 2, 3, and 4 exacerbation of the patients treated with ICS/LABA are lower than those treated without ICS/LABA (14.49 vs. 15.01%, 11.94% vs. 19.12%, 6.51% vs. 12.92% and 4.10% vs. 9.35%). The difference got a statistical significance Chronic obstructive pulmonary disease (COPD) and gastroesophageal reflux disease (GERD), two comorbidities related to asthma, were risk factors for asthma exacerbation. Finally, patients who suffered from exacerbations produced a heavier economic burden compared to the patients who never suffered exacerbations (mean costs are ¥3,339.67 vs. ¥968.45 separately). These results provide a reference for clinicians and patients to obtain a better treatment and therapy strategy management for people living with asthma.

3 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
BSBin Shang
Bin Shang
XLXiangguo Li
Xiangguo Li
YXYu Xu
Yu Xu
WRWenxin Ren
Wenxin Ren
JWJunren Wang
Junren Wang
JSJian Sun
Jian Sun
Background: Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. To obtain a better understanding of the clinical status and disease burden of patients with asthma in China. Methods: A retrospective study based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (n = 31,082) was carried out. The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to GINA 2018. Results: The results revealed that the majority (75.0%) of patients suffered from mild asthma. Patients treated with ICS/LABA at emergency department visits had lower frequencies of exacerbations in the following year compared with non-ICS/LABA treated patients.The incidence rates for 1 exacerbation are 14.49% vs 15.01 for the patients treated with ICS/LABA and without. The rates are 11.94% and 19.12% for 2 exacerbations above. The numbers are 6.51% vs 12.92% for 3 exacerbations above. The rates are 4.10% vs 9.35% for 4 exacerbations above. Also the difference got the statistical significance(p <0.001), COPD and GRED, two comorbidities related to asthma, were risk factors for asthma exacerbation. Finally, patients who suffered from exacerbations produced a heavier economic burden compared to the patients who never suffered exacerbations(mean costs are ¥3,339.67 vs ¥968.45 separately). Conclusions: These results provide a reference for clinicians and patients to obtain a better treatment and therapy strategy management for asthma sufferers.